World Journal of Gastrointestinal Oncology最新文献

{"title":"Neutrophil-albumin ratio and multi-phase computed tomography for lymph node metastasis in pancreatic cancer.","authors":"Huan Wang, Tian-Yu Fu, Fang Zhang, Fei-Chao Kang, Zhong-Wei Sun","doi":"10.4251/wjgo.v17.i12.113879","DOIUrl":"10.4251/wjgo.v17.i12.113879","url":null,"abstract":"<p><strong>Background: </strong>Reliable preoperative detection of lymph node metastasis (LNM) in pancreatic cancer remains elusive: Conventional computed tomography (CT) underestimates micrometastases, and carbohydrate antigen 19-9 is hampered by low specificity. The neutrophil-albumin ratio (NAR) simultaneously reflects systemic inflammation and nutritional depletion, but its contribution to LNM prediction in pancreatic cancer is unexplored. We hypothesised that integrating NAR with multi-phase CT findings would significantly improve the accuracy of preoperative LNM assessment in patients undergoing curative-intent resection.</p><p><strong>Aim: </strong>To determine whether preoperative NAR plus multi-phase CT reliably predicts nodal metastasis in pancreatic cancer.</p><p><strong>Methods: </strong>In this single-centre retrospective cohort study (February 2022 to February 2025, Ordos Central Hospital, China), 129 consecutive patients undergoing curative pancreatic resection were histologically classified as LNM⁺ (<i>n</i> = 61) and LNM^- (<i>n</i> = 68). Preoperative NAR and platelet-albumin ratio (PAR) were calculated; optimal cut-offs were determined with X-tile. Multi-phase CT images were re-reviewed by two blinded radiologists. Independent predictors of nodal metastasis were identified by multivariate logistic regression, and model performance was evaluated with receiver operating characteristic (ROC) analysis.</p><p><strong>Results: </strong>Between the two cohorts, univariate comparison revealed significant divergence in age, tumour diameter, concomitant hemangioma thrombosis, PAR, NAR, and CT-detected nodal status (<i>P</i> < 0.05). Subsequent multivariate modelling identified hemangioma thrombosis, PAR above 6.35, NAR exceeding 0.13, and radiologically positive lymph nodes as independent predictors of nodal metastasis (<i>P</i> < 0.05). ROC evaluation indicated that the NAR-plus-CT-nodes model (model 1) reached an area under the curve (AUC) of 0.758, whereas the four-variable composite (model 3) achieved the best performance with an AUC of 0.830 (95%CI: 0.753-0.890), sensitivity 83.61%, and specificity 67.65%.</p><p><strong>Conclusion: </strong>The model 3 (NAR > 0.13, PAR > 6.35, CT nodal positivity, hemangioma thrombosis) provides robust, clinically actionable preoperative identification of pancreatic cancer patients at high risk of LNM.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 12","pages":"113879"},"PeriodicalIF":2.5,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145889987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the blank page: Frequentist and Bayesian perspectives on risk prediction algorithms.","authors":"Francisco Tustumi, Felipe Antonio Boff Maegawa, Pedro Luiz Serrano Uson Junior","doi":"10.4251/wjgo.v17.i12.113988","DOIUrl":"10.4251/wjgo.v17.i12.113988","url":null,"abstract":"<p><p>Risk prediction has long been a cornerstone of surgical oncology, enabling surgeons to anticipate complications, tailor perioperative care, and improve outcomes. With the rise of artificial intelligence, machine learning (ML) models are increasingly being applied to predict outcomes, highlighting the growing significance of data-driven methods for clinical decision-making. Currently, frequentist approaches dominate prediction models, including most ML algorithms; these rely exclusively on observed datasets and risk overlooking the cumulative value of prior clinical knowledge. In contrast, Bayesian reasoning formally integrates existing evidence with new data. In this letter, we examine the strengths of frequentist-based prediction models, discuss how Bayesian methods may improve predictive accuracy, and argue that combining both approaches offers a promising path toward more robust, interpretable, and clinically useful prediction tools in surgery. This integration can yield robust, interpretable, and clinically relevant tools that advance personalized surgical care.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 12","pages":"113988"},"PeriodicalIF":2.5,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interlaced roles of mitochondrial DNA in colorectal cancer: Liquid-biopsy biomarkers, nuclear mtDNA-driven genomic instability, and mito-encoded micro peptide signaling.","authors":"Thai-Hau Koo, Xue-Bin Leong, Yi-Lin Lee, Firdaus Hayati, Andee Dzulkarnaen Zakaria","doi":"10.4251/wjgo.v17.i12.112753","DOIUrl":"10.4251/wjgo.v17.i12.112753","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is a widely occurring malignancy with significant mortality on a global scale, making up close to 10% of all diagnosed cancers in 2020. While traditional CRC diagnostics and research have focused on nuclear genomic alterations, emerging evidence has highlighted the multifaceted roles of mitochondrial DNA (mtDNA) in the pathogenesis and clinical management of CRC. In this review, we examine three interlaced aspects of mtDNA in CRC: (1) Liquid biopsy biomarkers: Cell-free mtDNA circulating in the blood serving as a minimally invasive diagnostic and monitoring tool; (2) Nuclear mtDNA (NUMT)-driven genomic instability: The somatic nuclear incorporation of mtDNA (NUMT segments, or NUMT), contributing to mutational burden and chromosomal disruption in tumours; and (3) Mitochondria-encoded micropeptide signaling - small peptides encoded by the mtDNA that modulate cellular pathways and tumour behaviour. Recent high-impact studies have demonstrated that tumour-derived mtDNA in biofluids can augment cancer detection sensitivity, although technical challenges remain due to mtDNA fragmentation and background noise. Meanwhile, genomic analyses have uncovered a significant increase in NUMT insertion events in CRC cells, linking mitochondrial genome escape to nuclear genome instability and identifying potential numtogenesis suppressor genes. A novel dimension of mito-nuclear interactions in cancer was discovered in mitochondrial microproteins, such as humanin and mitochondrial open reading frame of the 12S rRNA type-c. Humanin exhibits both tumour-promoting and cytoprotective properties under specific conditions, while mitochondrial open reading frame of the 12S rRNA type-c possesses tumour-suppressive activities under other conditions. The outcomes of clinical, mechanistic, and translational research, revealing how mtDNA-based biomarkers and involvement contribute towards early detection, prognostication, and treatment of CRC, are presented.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 12","pages":"112753"},"PeriodicalIF":2.5,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145889805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term survival after treatment of gastric cancer with S-1 plus oxaliplatin regimen and sintilimab: A case report.","authors":"Jun Pan, Ping Li, Yu-He Zhou, Ting-Ting Pan, Yi-Tian Chen, Xiao-Yuan Chu","doi":"10.4251/wjgo.v17.i12.112853","DOIUrl":"10.4251/wjgo.v17.i12.112853","url":null,"abstract":"<p><strong>Background: </strong>Treatment of metastatic gastric cancer (mGC) relies primarily on chemotherapy, which can be effectively combined with immunotherapy. Despite these interventions, overall survival remains suboptimal.</p><p><strong>Case summary: </strong>We report a patient with mGC who received S-1 plus oxaliplatin with sintilimab as first-line therapy, followed by maintenance therapy with S-1 and sintilimab. After 6 months, a partial response was observed, with a 71.7% reduction in the target lesion. After 13 months, the reduction reached 76.3%. Treatment was temporarily paused for 6 months due to a pulmonary infection. Upon re-evaluation 6 months later, the tumor continued to regress, with a 79.4% reduction in the target lesion. The original regimen was then resumed. From diagnosis to date, progression-free survival has reached 23 months.</p><p><strong>Conclusion: </strong>Sintilimab combined with chemotherapy demonstrated improved progression-free survival and warrants further investigation in mGC.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 12","pages":"112853"},"PeriodicalIF":2.5,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145889938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of cryoablation in treating locally advanced pancreatic cancer.","authors":"Li-Min Kang, Xiao-Long He, Li Lang, A-Yong Wang, Xian Wang, Yu-Hao Liu, Ying-Hong Zhao, Lei Xu, Fa-Kun Yu, Fu-Wei Zhang","doi":"10.4251/wjgo.v17.i12.113387","DOIUrl":"10.4251/wjgo.v17.i12.113387","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic cancer has an extremely poor prognosis. Although surgery is the first-line treatment for pancreatic cancer, its role is ultimately limited because patients often present too late for resection. Thus, multidisciplinary treatment approaches are needed. In particular, chemotherapy, targeted therapy, and immunotherapy can be ineffective for locally advanced pancreatic cancer (LAPC) because of its resistance to these modalities, but cryoablation has shown significant promise for treating this entity and prolonging survival.</p><p><strong>Aim: </strong>To investigate the safety and efficacy of cryoablation for LAPC.</p><p><strong>Methods: </strong>Clinical and laboratory data, including surgical procedure, postoperative complications, immunobiochemical markers (<i>e.g.</i>, carbohydrate antigen 19-9), and follow-up visits, of 24 LAPC patients treated with cryoablation at the department of hepatobiliary and pancreatic surgery of our hospital from January 2023 to December 2024 were retrospectively analyzed.</p><p><strong>Results: </strong>Surgery was smooth in all patients, with no perioperative deaths. Postoperative pancreatic fistulas occurred in 18 patients (75.0%), including biochemical leak in 14 cases and grade B (fistula) in 4 cases. Three patients (12.5%) had delayed gastric emptying. The carbohydrate antigen 19-9 level remained low on postoperative day 30 (<i>P</i> < 0.05). Immune markers (natural killer cells and tumor necrosis factor-alpha) significantly increased on days 7 and 30 (<i>P</i> < 0.01 or <i>P</i> < 0.05), whereas cluster of differentiation CD4+ T cells levels on day 30 significantly differed from baseline. Day 30 pain scores were significantly lower than preoperative ones (<i>P</i> < 0.01). Tumor volume was reduced on postoperative computed tomography. Survival was prolonged. The overall survival time of LAPC patients treated with cryoablation was 16.8 months.</p><p><strong>Conclusion: </strong>Cryoablation can directly inactivate LAPC and boost immunity, thus delaying tumor progression, alleviating pain, improving quality of life, and prolonging survivals. Therefore, it is a safe and effective treatment option for LAPC.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 12","pages":"113387"},"PeriodicalIF":2.5,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754296/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning survival prediction in esophageal cancer using radiomics and body composition from pretreatment and follow-up T12-level computed tomography.","authors":"Ming-Cheng Liu, Yung-Yin Cheng, Shao-Chieh Lin, Chih-Hung Lin, Cheng-Yen Chuang, Wen-Hsien Chen, Chun-Han Liao, Chia-Hong Hsieh, Mei-Fang Hsieh, Yi-Jui Liu","doi":"10.4251/wjgo.v17.i12.112873","DOIUrl":"10.4251/wjgo.v17.i12.112873","url":null,"abstract":"<p><strong>Background: </strong>Esophageal cancer carries a poor prognosis with low 5-year survival rates and limited early detection options. The skeletal muscle index at the L3 vertebral level is a well-established prognostic marker in esophageal cancer, but most follow-up computed tomography (CT) scans do not extend to L3 and limiting its utility. Radiomics has emerged as a powerful tool for extracting prognostic information from medical images.</p><p><strong>Aim: </strong>To evaluate the influential features for esophageal cancer prognosis by integrating radiomic and body composition-based indices of skeletal muscle and adipose tissue at the T12 level from both pretreatment and follow-up CT images, in order to assess their value in predicting overall survival (OS).</p><p><strong>Methods: </strong>This retrospective study included 212 esophageal cancer patients who underwent concurrent chemoradiotherapy, with both pretreatment and follow-up chest CT scans available. Body organ analysis (BOA) and radiomic features were extracted from skeletal muscle and adipose tissue at the T12 level using automated tools. Four feature subsets (no-radiomics, pretreatment only, follow-up only, and combined inputs) were developed using logistic regression (LR) with least absolute shrinkage and selection operator for feature selection, followed by Cox regression. Prognostic models - including nomogram, support vector classifier, LR, and extra trees classifier - were constructed to predict 1-, 2-, and 3-year OS.</p><p><strong>Results: </strong>The model integrating both BOA and radiomics from pretreatment and follow-up CT, combined with clinical data, achieved the best performance for 2-year OS prediction, with an area under the time-dependent receiver operating characteristic curve of 0.91, sensitivity of 0.81, and specificity of 0.88 using the LR model. The most predictive features included both clinical variables, body composition indices, and radiomic features, particularly from follow-up VAT. Follow-up imaging contributed significantly to model performance, reinforcing its value in treatment response evaluation.</p><p><strong>Conclusion: </strong>This is the first study to demonstrate that BOA indices and their corresponding radiomics at the T12-level from both pretreatment and follow-up CT scans - combined with clinical data - can provide accurate prognostic information for esophageal cancer. This approach offers a practical alternative when L3-level imaging is unavailable and supports the clinical integration of automated T12-based imaging biomarkers. The integration of these imaging features with clinical parameters enhances the prediction of survival outcomes and contributes to non-invasive, personalized treatment planning.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 12","pages":"112873"},"PeriodicalIF":2.5,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754302/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and prognostic analysis of three hundred and nineteen cases of primary gastrointestinal diffuse large B-cell lymphoma.","authors":"Jia-Jia Ma, Huan Zhang, Cui-Cui Wang, Wen-Li Ji, Ying Zhao, Xin-Xia Li","doi":"10.4251/wjgo.v17.i12.113661","DOIUrl":"10.4251/wjgo.v17.i12.113661","url":null,"abstract":"<p><strong>Background: </strong>Primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL), the most prevalent extranodal non-Hodgkin lymphoma, poses significant diagnostic and therapeutic challenges due to its non-specific symptoms and poor prognosis.</p><p><strong>Aim: </strong>To develop and validate a risk model for the early identification of PGI-DLBCL using Least Absolute Shrinkage and Selection-Cox regression, with the aim of guiding clinical decision-making.</p><p><strong>Methods: </strong>The clinical data of patients diagnosed with PGI-DLBCL at the Tumor Hospital Affiliated to Xinjiang Medical University were analyzed retrospectively from January 2010 to April 2022.</p><p><strong>Results: </strong>A total of 319 patients with PGI-DLBCL were included and divided into training (<i>n</i> = 223) and validation (<i>n</i> = 96) cohorts. The median age was 55 years, with 48.9% male and 51.1% female patients. Key clinical features included Eastern Cooperative Oncology Group performance status ≥ 2 (40.8%), advanced-stage disease (stage IV: 27.6%), extranodal involvement ≥ 2 sites (47%), tumor > 5 cm (46.1%), elevated beta-2 microglobulin (50.5%), elevated lactate dehydrogenase (27%), high International Prognostic Index (3-5: 69.9%), non-germinal center B-cell-like subtype (59.9%), and B symptoms (55.8%). Immunohistochemical analysis showed frequent expression of CD10 (51.1%), B-cell lymphoma 6 (53.3%), multiple myeloma oncogene 1 (40.1%), B-cell lymphoma 2 (49.2%), myelocytomatosis viral oncogene homolog (48.3%), Ki-67 (67.1%), and CD5 (42.6%); Epstein-Barr virus-encoded RNA was positive in 3.1%. Based on Least Absolute Shrinkage and Selection regression and subsequent univariate and multivariate Cox regression analyses, extranodal sites ≥ 2, B symptoms, mixed lesion type, and negative multiple myeloma oncogene 1 expression were identified as independent risk factors for PGI-DLBCL. The risk model stratified patients into high- and low-risk groups with significantly different overall survival (<i>P</i> < 0.05). Area under the curve values for 1-, 3-, and 5-year overall survival were 0.625, 0.663, and 0.723 in the training cohort, with consistent performance in the validation cohort. Decision curve analysis indicated favorable clinical utility.</p><p><strong>Conclusion: </strong>PGI-DLBCL in our cohort showed distinctive clinical features and a predominance of the non-germinal center B-cell-like subtype. Decision curve analysis confirmed the clinical applicability of our prognostic model. Although molecular biomarkers will be needed to improve predictive precision, our model offers a practical tool for early risk identification and individualized management in clinical practice.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 12","pages":"113661"},"PeriodicalIF":2.5,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754328/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer-associated fibroblasts, clinicopathological characteristics and prognosis of liver cancer: A systematic review and meta-analysis based on real-world research.","authors":"Yu-Hao Wei, Wen-Jing Jiang, Shi-Qian Wang, Yu-Long Cai, Xue-Lei Ma","doi":"10.4251/wjgo.v17.i12.110395","DOIUrl":"10.4251/wjgo.v17.i12.110395","url":null,"abstract":"<p><strong>Background: </strong>Cancer-associated fibroblasts (CAFs), crucial components of the tumor microenvironment in primary and metastatic tumors, can impact the activity of cancer cells and contribute to their progression. Given their extensive interactions with cancer cells and other stromal cells, we aimed to evaluate the prognostic value of CAFs in patients with liver cancer (LC).</p><p><strong>Aim: </strong>To investigate the association between CAF expression and clinicopathological characteristics as well as overall survival (OS) in patients with LC, including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA).</p><p><strong>Methods: </strong>We performed a meta-analysis of cohort studies with available data on the effects of CAF expression on both clinicopathological characteristics and OS <i>via</i> hazard ratios (HRs) and risk ratios with 95% confidence intervals (CIs). Studies were subgrouped on the basis of CAF markers and cancer type, and the subgroup effects of CAF expression on both HCC and iCCA were analyzed through meta-regression. The Newcastle-Ottawa Scale was used to evaluate the included studies to guarantee their quality and minimize the possibility of bias.</p><p><strong>Results: </strong>Nine trials were selected and included a total of 1518 patients. According to our primary meta-analysis, the expression of CAFs in LC patients was significantly associated with a decrease in OS (LC: HR: 1.62; 95%CI: 1.34-1.97; <i>P</i> < 0.001; HCC: HR: 1.67; 95%CI: 1.34-2.07; <i>P</i> < 0.001; iCCA: HR: 1.47; 95%CI: 0.97-2.23; <i>P</i> = 0.07); nevertheless, it was not significantly associated with almost all clinicopathologic characteristics, including tumor size, venous infiltration, alpha-fetoprotein level, and differentiation grade. According to the subgroup analysis of smooth muscle actin (SMA) markers in both HCC patients and iCCA patients, high CAF expression in HCC (HR: 2.29; 95%CI: 1.01-5.22; <i>P</i> = 0.048) and iCCA (HR: 2.04; 95%CI: 1.09-3.81; <i>P</i> = 0.025) patients was a significant indicator of poor OS. Moreover, the clinicopathological characteristics were also verified by the SMA marker, which had a nearly significant effect on the venous infiltration of iCCA (risk ratio: 2.70; 95%CI: 0.97-7.49; <i>P</i> = 0.057).</p><p><strong>Conclusion: </strong>High CAF expression, evaluated by both mixed markers and SMAs, is significantly associated with poor OS in patients with LC, including both HCC patients and iCCA patients. However, further research is necessary since how CAF expression and clinicopathologic features are related is yet unknown.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 12","pages":"110395"},"PeriodicalIF":2.5,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754341/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel insights into SLC16A8 in colorectal cancer.","authors":"Jing-Yuan Li, Guang Ji, Yan-Qi Dang","doi":"10.4251/wjgo.v17.i12.112894","DOIUrl":"10.4251/wjgo.v17.i12.112894","url":null,"abstract":"<p><p>Colorectal cancer (CRC) ranks as the third most prevalent cancer globally, and hypoxia-induced metabolic reprogramming is considered a key driver of its malignant progression. We read with interest the article by Tian <i>et al</i>, which examines the role of solute carrier family 16 member 8 (SLC16A8) in regulating the tumor microenvironment. The study provides valuable evidence supporting the dual mechanisms by which SLC16A8 influences CRC pathogenesis and offers new directions for clinical research. This work demonstrates that activation of the HIF-1α/SLC16A8 axis under hypoxic conditions enhances glycolytic flux and lactate production. Additionally, SLC16A8 facilitates lactate transport, thereby inducing endothelial-mesenchymal transition-a finding that underscores its functional significance in shaping the tumor microenvironment. We believe the mechanistic insights presented in this study contribute meaningfully to the understanding of CRC biology. We would like to share our interpretations and hope to further discuss with the authors certain unexplored aspects and potential connections in this area.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 12","pages":"112894"},"PeriodicalIF":2.5,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor calcification and sustained complete response after chemoembolization in hepatocellular carcinoma: Two case reports and review of literature.","authors":"Sultan R Alharbi","doi":"10.4251/wjgo.v17.i12.113341","DOIUrl":"10.4251/wjgo.v17.i12.113341","url":null,"abstract":"<p><strong>Background: </strong>Transarterial chemoembolization (TACE) is a widely accepted palliative therapy modality for unresectable hepatocellular carcinoma (HCC). Although it is rarely curative, complete radiological response can be achieved in selected patients, leading to prolonged survival. Post-treatment tumoral calcification is an uncommon imaging finding in HCC and is rarely reported after drug-eluting beads TACE (DEB-TACE).</p><p><strong>Case summary: </strong>Two patients with large, solitary HCCs (> 5 cm) were treated with DEB-TACE, and both achieved complete radiological response after two treatment sessions. Approximately 1 year after DEB-TACE, imaging demonstrated progressive peripheral tumoral calcification. Over 6 years of follow-up, both patients remained in remission with preserved liver function.</p><p><strong>Conclusion: </strong>These two cases highlight the potential for complete remission and long-term survival in selected patients with large HCC following DEB-TACE. The appearance of peripheral calcification may represent a late imaging marker of effective tumor necrosis and durable treatment response although prospective studies are warranted to clarify its prognostic value.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":"17 12","pages":"113341"},"PeriodicalIF":2.5,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12754280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}